280 related articles for article (PubMed ID: 31718986)
1. Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis.
Rozenfeld PA; de Los Angeles Bolla M; Quieto P; Pisani A; Feriozzi S; Neuman P; Bondar C
Mol Genet Metab; 2020 Feb; 129(2):132-141. PubMed ID: 31718986
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic pathways of renal damage in Fabry nephropathy: interplay between immune cell infiltration, apoptosis and fibrosis.
Bondar C; de Bolla MLA; Neumann P; Pisani A; Feriozzi S; Rozenfeld PA
J Nephrol; 2024 Apr; 37(3):625-634. PubMed ID: 38512375
[TBL] [Abstract][Full Text] [Related]
3. Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy.
Lee MH; Choi EN; Jeon YJ; Jung SC
Int J Mol Med; 2012 Dec; 30(6):1275-80. PubMed ID: 23007467
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease.
Goumenos DS; Tsamandas AC; Oldroyd S; Sotsiou F; Tsakas S; Petropoulou C; Bonikos D; El Nahas AM; Vlachojannis JG
Nephron; 2001 Mar; 87(3):240-8. PubMed ID: 11287759
[TBL] [Abstract][Full Text] [Related]
5. Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts.
Abbate M; Zoja C; Rottoli D; Corna D; Tomasoni S; Remuzzi G
Kidney Int; 2002 Jun; 61(6):2066-77. PubMed ID: 12028447
[TBL] [Abstract][Full Text] [Related]
6. Renal pathological changes in Fabry disease.
Sessa A; Meroni M; Battini G; Maglio A; Brambilla PL; Bertella M; Nebuloni M; Pallotti F; Giordano F; Bertagnolio B; Tosoni A
J Inherit Metab Dis; 2001; 24 Suppl 2():66-70; discussion 65. PubMed ID: 11758681
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-β1 short hairpin RNA inhibits renal allograft fibrosis.
Yin ZK; Wu XH; Xia YG; Luo CL
Chin Med J (Engl); 2011 Mar; 124(5):655-63. PubMed ID: 21518553
[TBL] [Abstract][Full Text] [Related]
8. Myofibroblast phenotypes expression in experimental renal scarring.
Muchaneta-Kubara EC; el Nahas AM
Nephrol Dial Transplant; 1997 May; 12(5):904-15. PubMed ID: 9175042
[TBL] [Abstract][Full Text] [Related]
9. Myofibroblasts and the progression of crescentic glomerulonephritis.
Goumenos D; Tsomi K; Iatrou C; Oldroyd S; Sungur A; Papaioannides D; Moustakas G; Ziroyannis P; Mountokalakis T; El Nahas AM
Nephrol Dial Transplant; 1998 Jul; 13(7):1652-61. PubMed ID: 9681707
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro.
Fan JM; Ng YY; Hill PA; Nikolic-Paterson DJ; Mu W; Atkins RC; Lan HY
Kidney Int; 1999 Oct; 56(4):1455-67. PubMed ID: 10504497
[TBL] [Abstract][Full Text] [Related]
11. C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy.
Stangou M; Alexopoulos E; Pantzaki A; Leonstini M; Memmos D
Scand J Urol Nephrol; 2008; 42(4):373-80. PubMed ID: 19230171
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and myofibroblast expression in human glomerular disease: a possible link with transforming growth factor-beta-1.
Goumenos DS; Tsamandas AC; El Nahas AM; Thomas G; Tsakas S; Sotsiou F; Bonikos DS; Vlachojannis JG
Nephron; 2002 Oct; 92(2):287-96. PubMed ID: 12218305
[TBL] [Abstract][Full Text] [Related]
13. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulo-interstitial fibrosis.
Lane A; Johnson DW; Pat B; Winterford C; Endre Z; Wei M; Gobe GC
Growth Factors; 2002 Sep; 20(3):109-19. PubMed ID: 12519014
[TBL] [Abstract][Full Text] [Related]
14. Tubular phenotypic change in progressive tubulointerstitial fibrosis in human glomerulonephritis.
Jinde K; Nikolic-Paterson DJ; Huang XR; Sakai H; Kurokawa K; Atkins RC; Lan HY
Am J Kidney Dis; 2001 Oct; 38(4):761-9. PubMed ID: 11576879
[TBL] [Abstract][Full Text] [Related]
15. Opposite role of CD44-standard and CD44-variant-3 in tubular injury and development of renal fibrosis during chronic obstructive nephropathy.
Rampanelli E; Rouschop KM; Claessen N; Teske GJ; Pals ST; Leemans JC; Florquin S
Kidney Int; 2014 Sep; 86(3):558-69. PubMed ID: 24717295
[TBL] [Abstract][Full Text] [Related]
16. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
17. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
Fogo AB; Bostad L; Svarstad E; Cook WJ; Moll S; Barbey F; Geldenhuys L; West M; Ferluga D; Vujkovac B; Howie AJ; Burns A; Reeve R; Waldek S; Noël LH; Grünfeld JP; Valbuena C; Oliveira JP; Müller J; Breunig F; Zhang X; Warnock DG;
Nephrol Dial Transplant; 2010 Jul; 25(7):2168-77. PubMed ID: 19833663
[TBL] [Abstract][Full Text] [Related]
18. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
19. Profibrotic effects of angiotensin II and transforming growth factor beta on feline kidney epithelial cells.
van Beusekom CD; Zimmering TM
J Feline Med Surg; 2019 Aug; 21(8):780-787. PubMed ID: 30345862
[TBL] [Abstract][Full Text] [Related]
20. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
